Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.
The FDA's independent panel of advisors will meet in June to discuss the Pfizer and Moderna COVID-19 vaccines for children under age 5, as well as the Novavax vaccine for adults, according to an FDA announcement released Friday.
On June 7, the FDA's vaccine committee will review the Novavax shot, which could become the first new COVID-19 vaccine to hit the U.S. market in more than a year. The shot is already authorized in more than three dozen countries, including across Europe.
The FDA has also selected three possible dates — June 8, 21, and 22 — to discuss the shots for kids under age 5. The dates are tentative because the companies haven't completed their submissions, the agency said.
However, the committee decided to announce plans to hold virtual meetings "in anticipation of complete submissions of emergency use authorization requests in the coming months that have been publicly announced by COVID-19 vaccine manufacturers."
Moderna has said it plans to complete its submission by the end of next week, according to CBS News. Pfizer has said its clinical trial data could be complete by June.
In addition, the FDA committee will meet on June 28 to discuss whether the coronavirus strain composition in current vaccines should be modified, and if so, which strains should be used for vaccines produced for fall 2022.
